Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved to reduce cardiovascular disease in those with type 2 diabetes mellitus (T2DM). Longer acting GLP-1RAs, liraglutide and semaglutide, demonstrate a signi fi cant reduction in major cardiovascular events not observed in short-acting GLP-1RAs or dipeptidyl peptidase-4 inhibitors. 1 The mechanism by which GLP-1RAs improve cardiovascular risk in T2DM is likely multifactorial with indi-rect effects on platelet aggregation postulated. 1 Platelet activation, independent from hemostasis, contributes to in fl ammation in the cardiovascular system. Prior in vitro studies suggest that GLP-1RAs reduce thrombin-induced platelet aggregation via GLP-1R – independent mechanisms and enhance nitric oxide inhibition of adenosine-, collagen-, and arach-idonic acid – induced platelet aggregation in normo-cholesterolemic states, but no evidence shows a direct GLP-1R effect on platelets. 2 Thromboxane A 2 (TX) is a proin fl ammatory mediator in cardiovascular disease, particularly in T2DM. 3 Patients with T2DM demonstrate elevated platelet TX production and increased urinary TX metabolites. TX is generated by endothelial cells, activated platelets, and macro-phages. It binds the TX receptor on platelets to enhance activation and aggregation. We hypothe-sized that the GLP-1RA liraglutide would directly attenuate TX-induced platelet activation independent of weight loss or changes in glycemic control. for a lack of observed DDP-4 inhibitor effect on TX-induced platelet activation. TX-mediated platelet activation heightens both thrombosis and platelet-mediated in fl ammation. Thus, the GLP-1R may represent a druggable platelet inhibitory receptor relevant in thrombotic and platelet-mediated in fl ammation disease. GLP-1RA – mediated attenuation of platelet activation tone may contribute to the clinical bene fi t observed in cardiovascular outcomes in T2DM. The low doses and short duration of exposure needed to attenuate platelet aggregation in prediabetic adults supports a weight loss – independent clinical bene fi t from GLP-1RAs in cardiovascular disease. This work points toward an expansion of the clinical populations that might bene fi t from treatment. Further study of the relationship between early attenuation of TX-mediated platelet activation following GLP-1RA exposure and thrombotic clinical outcomes are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Cited by
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“GLP1 might also reduce platelet aggregation; however, expression of the canonical GLP1R in platelets remains uncertain 122 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“Moreover, the binding of LUXendin645 and the reduction of platelet aggregation by liraglutide was attenuated by the GLP-1R antagonist exendin(9–39) [113].”
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Liraglutide attenuates thromboxane-induced platelet aggregation in people with obesity after several weeks of treatment 147 , findings associated with platelet binding of a fluorescent GLP-1RA to platelets ex vivo.”
Metadata
- Authors
- Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., Nian, H., Mashayekhi, M., Silver, H. J., Luther, J. M., Brown, N. J., Peebles, R. S., & Niswender, K.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 7
- Issue
- 7
- Pages
- 713-715
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W4287843575
- Cited by
- 41
- References
- 1
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation. https://app.cochat.ai/papers/10.1016/j.jacbts.2022.04.004
- The paper
- Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., Nian, H., Mashayekhi, M., Silver, H. J., Luther, J. M., Brown, N. J., Peebles, R. S., & Niswender, K. (2022). Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation. JACC: Basic to Translational Science. https://doi.org/10.1016/j.jacbts.2022.04.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.